1268516-32-0

Basic information

• Product Name: benzyl ((3S)-4-oxotetrahydro-2H-pyran-3-yl)carbamate
• Synonyms: benzyl ((3S)-4-oxotetrahydro-2H-pyran-3-yl)carbamate
• CAS NO: 1268516-32-0
• Molecular Weight: 249.266
• Mol File: 1268516-32-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: benzyl ((3S)-4-oxotetrahydro-2H-pyran-3-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl ((3S)-4-oxotetrahydro-2H-pyran-3-yl)carbamate(1268516-32-0)
• EPA Substance Registry System: benzyl ((3S)-4-oxotetrahydro-2H-pyran-3-yl)carbamate(1268516-32-0)

Safety Data

• Hazardous Substances Data: 1268516-32-0(Hazardous Substances Data)

Upstream product

• 1268516-33-1 benzyl ((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)carbamate 
• 693245-80-6 4,4-dimethoxy-5,6-dihydro-2H-pyran-3(4H)-one 
• 104681-92-7 4,4-dimethoxytetrahydro-2H-pyran-3-ol 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 1268516-31-9 (3S)-4,4-dimethoxytetrahydro-2H-pyran-3-amine 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1240390-32-2 2-amino-1,5-anhydro-2,4-dideoxy-L-threo-pentitol 
• 1268516-33-1 benzyl ((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)carbamate 

Relevant articles and documents

POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE

Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A′, R1, R2 /su

QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to quinoline amide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

PYRIDOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.